权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Nonhuman Primate Antibody Resource for Immune Cell Depletion

用于消除免疫细胞的非人灵长类动物抗体资源

基本信息

批准号：
10168817
负责人：
Kathleen Engelman
金额：
$ 32.36万
依托单位：
UNIV OF MASSACHUSETTS MED SCH WORCESTER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-01-01 至 2024-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10168817
关键词：
2019-nCoV Address Amino Acids Animal Disease Models Animal Model Animals Antibodies Award Biocompatible Materials Biological Biological Assay Biomedical Research California Cells Containment Coronavirus Detection Development Disease Engineering Enzyme-Linked Immunosorbent Assay Funding Generations Goals Grant Human Image Immune Immunity Immunoglobulin G Immunoglobulins Infection Infectious Agent Infrastructure Institution Laboratories Lateral Letters Macaca Macaca mulatta Measurement Methods Modeling Monkeys Monoclonal Antibodies Nature Parents Pathogenicity Pathology Patients Performance Preparation Primates Public Health Reagent Recombinant Antibody Recombinant Proteins Recombinants Reference Standards Reproducibility Research Research Infrastructure Research Institute Research Personnel Research Support Resources Rhesus SARS coronavirus Saliva Sampling Serological Serum Standardization Strategic Planning Testing Texas Time Training Validation Viral Antibodies Washington assay development base coronavirus disease diagnostic assay human disease human model improved member nonhuman primate pandemic disease programs reagent standard screening tool working group

项目摘要

Project Summary The Nonhuman Primate Reagent Resource (NHPRR) develops recombinant biological materials to support research with animal models of human diseases. In our parent P40 award, we produce and distribute approximately 400g of recombinant protein reagents per year. Therefore, we have the tools, expertise, and infrastructure to manufacture recombinant reagents and distribute them widely. Very recently, coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID) was declared a pandemic, which prompted the development of new animal models. Unfortunately, the potentially infectious nature of COVID samples has precluded the exchange of reference serum samples among centers developing monkey models of COVID. Thus, our plan is to create safe recombinant reference macaque immunoglobulin standards to facilitate the development and validation of reliable assays for the detection of pathogenic coronaviruses and antiviral antibodies in NHP animal models of COVID. Specifically, this supplement will fund the generation of the following reagents: recombinant coronavirus-reactive rhesus monoclonal IgGs (Aim 1) and NHP serum reference standards (Aim 2). These macaque reference antibody reagents will improve the performance and comparability of antibody-based assays for NHP models by facilitating serum assay development, proficiency training, and inter-laboratory performance comparisons at the NPRCs (see letters of support).

项目概要非人类灵长类动物试剂资源 (NHPRR) 开发重组生物材料来支持人类疾病的动物模型研究。在我们的母公司 P40 奖项中，我们制作并分发每年约400克重组蛋白试剂。因此，我们拥有工具、专业知识和生产重组试剂并广泛分销的基础设施。最近，冠状病毒严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 疾病 (COVID) 被宣布为大流行，这促进了新动物模型的开发。不幸的是，潜在的传染性新冠病毒样本导致猴子发育中心之间无法交换参考血清样本新冠肺炎模型。因此，我们的计划是创建安全的重组参考猕猴免疫球蛋白标准品促进用于检测致病性冠状病毒的可靠测定方法的开发和验证新冠肺炎 NHP 动物模型中的抗病毒抗体。具体来说，该补助金将资助产生以下试剂：重组冠状病毒反应性恒河猴单克隆 IgG（目标 1）和 NHP 血清参考标准（目标 2）。这些猕猴参考抗体试剂将提高性能和可比性通过促进血清测定开发、熟练程度培训和 NPRC 的实验室间性能比较（参见支持信）。